Overview

* MaxCyte ( MXCT ) Q2 total revenue falls 18% yr/yr, missing analyst expectations

* Core business revenue rises 8% yr/yr, but SPL revenue drops significantly

* Adjusted EBITDA loss widens, missing analyst expectations, per LSEG data

Outlook

* MaxCyte ( MXCT ) expects SPL Program-related revenue of $5 mln for 2025

* Company anticipates ending 2025 with at least $155 mln in cash

* MaxCyte ( MXCT ) forecasts core revenue flat to 10% decline vs 2024

* Company cites customer inventory management for lowered 2025 guidance

Result Drivers

* CORE BUSINESS GROWTH - Core business revenue increased by 8% in Q2 2025, driven by sales of instruments, consumables, and licenses

* SPL REVENUE DECLINE - SPL Program-related revenue fell significantly due to timing variability in milestone payments and royalties

* LOWERED GUIDANCE - MaxCyte ( MXCT ) lowered its 2025 guidance due to customer inventory management and pipeline reprioritization impacting expectations

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $8.20 $9.53

Revenue mln mln (6

Analysts

)

Q2 Net -$12.40

Income mln

Q2 Miss -$13.10 -$8.91

Adjusted mln mln (4

EBITDA Analysts

)

Q2 Cash $165.20

& mln

Investme

nts

Q2 Gross $7 mln

Profit

Q2 $21.20

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

* Wall Street's median 12-month price target for MaxCyte Inc ( MXCT ) is $6.50, about 68.3% above its August 5 closing price of $2.06

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)